stds-stis-hiv-aids-2017-scientifictracks-abstracts

2 / 17

Virology research J 2017 Vol 1 Issue 2
Page 14
Notes:
July 26-27, 2017 | Vancouver, Canada
WORLD CONFERENCE ON STDs, STIs & HIV/AIDS
alliedacademies
Increased availability of one pill-once daily antiretroviral
therapy (ART) combinations with greater potency and
tolerability has created a dynamic shift in prescribing
patterns towards simplification to these newer therapies.
In this presentation, we will identify common one pill-once
daily ART combinations and most current recommendations
for treatment of HIV. In an era of ART simplification
encouraged by an armamentarium of better therapies,
the HIV aging population is increasing. Given these trends,
the prevalence of comorbidities is also increasing in the
HIV aging population. One example includes the large HIV
Dutch ATHENA cohort projecting a significantly increased
prevalence in both the number of comorbidities (especially,
cardiovascular disease) and concomitant medications used
to treat these comorbidities by 2030. Consequences of
polypharmacy include increased pill burden, costs, drug-drug
interactions, and adverse effects. In this presentation we will
briefly discuss current and future polypharmacy trends in an
aging HIV population. Studies show that adherence to ART
is improved if HIV patients are taking fewer medications
on a daily basis. Although many strategies exist to reduce
polypharmacy to ensure sustainable success on ART, one
excellent measure may include precision medicine. In this
presentation, we will describe specific examples of how
using this personalized healthcare approach can serve
importantly in guiding choices in both ART and management
of common comorbidities in the HIV aging population.
Finally, we will conclude with factors affecting clinical uptake
of pharmacogenetic testing and discuss future implications.
Speaker Biography
Dr. Crutchley graduated from Duke University in 2001. He then received his doctorate
of Pharmacy from the University of North Carolina at Chapel Hill. Dr. Crutchley contin-
ued his education further by completing his PGY-1 Pharmacy Practice Residency at the
University of Texas at Tyler and his PGY-2 HIV Specialty Residency at the State Universi-
ty of New York at Buffalo. Since then, he has also completed a STAR Health Disparities
Fellowship through the University at North Texas Health Science Center at Fort Worth.
Dr. Crutchley is currently working as a Clinical Associate Professor at the University of
Houston, College of Pharmacy. He works as a HIV clinical pharmacist at Therapeutic
Concepts (private adult HIV clinic) and the Retrovirology Clinic at Texas Children’s Hos-
pital with HIV-infected children and adolescents. Dr. Crutchley established a new and
innovative PGY-2 HIV Ambulatory Care/Clinical Pharmacogenetics Residency Program
at the University of Houston. His research interests include complimentary alternative
medicine and pharmacogenetic approaches used to improve the quality of life and
lifespan of HIV-infected patients.
e:
Rustin Crutchley
University of Houston, USA
Precision medicine in the HIV aging population